Nextech Invest 13F annual report

Nextech Invest is an investment fund managing more than $594 billion ran by Marco Weibel. There are currently 13 companies in Mr. Weibel’s portfolio. The largest investments include Revolution Medicines Inc and Tyra Biosciences Inc, together worth $309 billion.

$594 billion Assets Under Management (AUM)

As of 7th August 2024, Nextech Invest’s top holding is 6,296,740 shares of Revolution Medicines Inc currently worth over $244 billion and making up 41.1% of the portfolio value. Relative to the number of outstanding shares of Revolution Medicines Inc, Nextech Invest owns more than approximately 0.1% of the company. In addition, the fund holds 4,055,861 shares of Tyra Biosciences Inc worth $64.9 billion. The third-largest holding is Tango Therapeutics Inc worth $47.5 billion and the next is Cargo Therapeutics Inc worth $43.4 billion, with 2,642,502 shares owned.

Currently, Nextech Invest's portfolio is worth at least $594 billion. The total portfolio value may be much higher due to cash assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.

Careers at Nextech Invest

The Nextech Invest office and employees reside in Zurich, Switzerland. According to the last 13-F report filed with the SEC, Marco Weibel serves as the Chief Financial Officer at Nextech Invest.

Recent trades

In the most recent 13F filing, Nextech Invest revealed that it had opened a new position in Context Therapeutics Inc and bought 7,419,355 shares worth $14.9 billion.

The investment fund also strengthened its position in Mersana Therapeutics Inc by buying 5,669,825 additional shares. This makes their stake in Mersana Therapeutics Inc total 9,526,146 shares worth $19.1 billion. Mersana Therapeutics Inc soared 3.1% in the past year.

One of the average hedge funds

The two most similar investment funds to Nextech Invest are Sendero Wealth Management and Bluesky Wealth Advisors. They manage $594 billion and $594 billion respectively.

Marco Weibel investment strategy

Nextech Invest’s portfolio is diversified across 2 sectors. Currently, their heaviest sector is Health Care — making up 67.8% of the total portfolio value. The fund focuses on investments in the United States as 46.2% of the portfolio companies are based in the United States.

The majority of the companies in the fund’s portfolio are large-cap stocks. Stocks with a size of more than $10 billion in market cap make up approximately 0.1% of the total holdings value. On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio. The average market cap of the portfolio companies is close to $1.04 billion.

The complete list of Nextech Invest trades based on 13F SEC filings

These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.

Security	Shares Owned	Value	Allocation
Revolution Medicines Inc	No change 6,296,740	$244,376,479,000	41.11%
Tyra Biosciences Inc	No change 4,055,861	$64,853,217,000	10.91%
Tango Therapeutics Inc	No change 5,533,980	$47,481,548,000	7.99%
Cargo Therapeutics Inc	No change 2,642,502	$43,389,883,000	7.30%
Arvinas Inc	No change 1,408,394	$37,491,448,000	6.31%
Oric Pharmaceuticals, Inc.	No change 5,285,714	$37,369,998,000	6.29%
Relay Therapeutics, Inc.	No change 3,846,409	$25,078,587,000	4.22%
Cullinan Oncology, LLC	No change 1,221,145	$21,296,769,000	3.58%
Mersana Therapeutics Inc	147.03% 9,526,146	$19,147,553,000	3.22%
Silence Therapeutics plc	No change 952,400	$18,095,600,000	3.04%
Ars Pharmaceuticals Inc	No change 1,910,029	$16,254,347,000	2.73%
Context Therapeutics Inc	Opened 7,419,355	$14,875,807,000	2.50%
Boundless Bio Inc	No change 1,228,069	$4,752,627,000	0.80%
No transactions found
Showing first 500 out of 13 holdings